These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 31216999)

  • 1. Association of plasma endothelial lipase levels on cognitive impairment.
    Yun SM; Park JY; Seo SW; Song J
    BMC Psychiatry; 2019 Jun; 19(1):187. PubMed ID: 31216999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum levels of vitamin E forms and risk of cognitive impairment in a Finnish cohort of older adults.
    Mangialasche F; Solomon A; Kåreholt I; Hooshmand B; Cecchetti R; Fratiglioni L; Soininen H; Laatikainen T; Mecocci P; Kivipelto M
    Exp Gerontol; 2013 Dec; 48(12):1428-35. PubMed ID: 24113154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of Plasma Neurofilament Light Chain and Mini-Mental State Examination Score Predicts Progression from Mild Cognitive Impairment to Alzheimer's Disease within 5 Years.
    Darmanthé N; Tabatabaei-Jafari H; Cherbuin N;
    J Alzheimers Dis; 2021; 82(3):951-964. PubMed ID: 34120902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.
    Portelius E; Zetterberg H; Skillbäck T; Törnqvist U; Andreasson U; Trojanowski JQ; Weiner MW; Shaw LM; Mattsson N; Blennow K;
    Brain; 2015 Nov; 138(Pt 11):3373-85. PubMed ID: 26373605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Andreasson U; Zetterberg H; Blennow K;
    JAMA Neurol; 2017 May; 74(5):557-566. PubMed ID: 28346578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer's disease (DELCODE).
    Jessen F; Spottke A; Boecker H; Brosseron F; Buerger K; Catak C; Fliessbach K; Franke C; Fuentes M; Heneka MT; Janowitz D; Kilimann I; Laske C; Menne F; Nestor P; Peters O; Priller J; Pross V; Ramirez A; Schneider A; Speck O; Spruth EJ; Teipel S; Vukovich R; Westerteicher C; Wiltfang J; Wolfsgruber S; Wagner M; Düzel E
    Alzheimers Res Ther; 2018 Feb; 10(1):15. PubMed ID: 29415768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anosognosia Is an Independent Predictor of Conversion From Mild Cognitive Impairment to Alzheimer's Disease and Is Associated With Reduced Brain Metabolism.
    Gerretsen P; Chung JK; Shah P; Plitman E; Iwata Y; Caravaggio F; Nakajima S; Pollock BG; Graff-Guerrero A;
    J Clin Psychiatry; 2017; 78(9):e1187-e1196. PubMed ID: 29022655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers for Early Diagnostic of Mild Cognitive Impairment in Type-2 Diabetes Patients: A Multicentre, Retrospective, Nested Case-Control Study.
    Xu ZP; Yang SL; Zhao S; Zheng CH; Li HH; Zhang Y; Huang RX; Li MZ; Gao Y; Zhang SJ; Zhan PY; Zhang LF; Deng L; Wei S; Liu YC; Ye JW; Ren HJ; Li N; Kong CX; Wang X; Fang L; Zhou QZ; Jiang HW; Li JR; Wang Q; Ke D; Liu GP; Wang JZ
    EBioMedicine; 2016 Mar; 5():105-13. PubMed ID: 27077117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-Density Lipoprotein Subclasses and Mild Cognitive Impairment: Study of Outcome and aPolipoproteins in Dementia (STOP-Dementia)1.
    Ohtani R; Nirengi S; Nakamura M; Murase N; Sainouchi M; Kuwata Y; Takata M; Masuda Y; Kotani K; Sakane N
    J Alzheimers Dis; 2018; 66(1):289-296. PubMed ID: 30248050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apolipoprotein A1 in Cerebrospinal Fluid and Plasma and Progression to Alzheimer's Disease in Non-Demented Elderly.
    Slot RE; Van Harten AC; Kester MI; Jongbloed W; Bouwman FH; Teunissen CE; Scheltens P; Veerhuis R; van der Flier WM
    J Alzheimers Dis; 2017; 56(2):687-697. PubMed ID: 28035918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Systemic inflammatory markers in age-associated cognitive impairment and Alzheimer's disease].
    Kliushnik TP; Androsova LV; Mikhaylova NM; Kolykhalov IV; Zozulya SA; Dupin AM
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(7):74-79. PubMed ID: 28805765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interrelationship between Mini-Mental State Examination scores and biochemical parameters in patients with mild cognitive impairment and Alzheimer's disease.
    Vasantharekha R; Priyanka HP; Swarnalingam T; Srinivasan AV; ThyagaRajan S
    Geriatr Gerontol Int; 2017 Oct; 17(10):1737-1745. PubMed ID: 27921357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevation of plasma soluble amyloid precursor protein beta in Alzheimer's disease.
    Yun SM; Cho SJ; Jo C; Park MH; Han C; Koh YH
    Arch Gerontol Geriatr; 2020; 87():103995. PubMed ID: 31874328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease.
    Zhang H; Therriault J; Kang MS; Ng KP; Pascoal TA; Rosa-Neto P; Gauthier S;
    Alzheimers Res Ther; 2018 Aug; 10(1):80. PubMed ID: 30115118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impaired Insulin Sensitivity and Secretion in Patients with Alzheimer's Disease: The Relationship with Other Atherosclerosis Risk Factors.
    Macesic M; Lalic NM; Kostic VS; Jotic A; Lalic K; Stefanova E; Milicic T; Lukic L; Gajovic JS; Krako N
    Curr Vasc Pharmacol; 2017; 15(2):158-166. PubMed ID: 27599805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer's disease.
    Baldeiras I; Santana I; Leitão MJ; Vieira D; Duro D; Mroczko B; Kornhuber J; Lewczuk P
    Alzheimers Res Ther; 2019 Jan; 11(1):2. PubMed ID: 30611311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral Brain-Derived Neurotrophic Factor Levels in Alzheimer's Disease and Mild Cognitive Impairment: a Comprehensive Systematic Review and Meta-analysis.
    Kim BY; Lee SH; Graham PL; Angelucci F; Lucia A; Pareja-Galeano H; Leyhe T; Turana Y; Lee IR; Yoon JH; Shin JI
    Mol Neurobiol; 2017 Nov; 54(9):7297-7311. PubMed ID: 27815832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
    Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
    Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between plasma CTRPs with cognitive impairment and neurodegeneration of Alzheimer's disease.
    Huang X; Zhao J; Wang Q; Yan T; Gou S; Zhu X; Yang L; Ye F; Zhang J; Wang Y; Yang S; Le W; Xiang Y
    CNS Neurosci Ther; 2024 Feb; 30(2):e14606. PubMed ID: 38334009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.